Revolutionizing oncology research
Detecting minute amounts of cancer-associated gene variants is essential in oncology research, enabling the development of vital biomarker knowledge. This knowledge is crucial for translational research as it helps bridge laboratory discoveries with clinical applications. Precise characterization of key variants further supports exploration into targeted treatment strategies and personalized medicine approaches.
Digital PCR (dPCR) provides accurate and reliable DNA measurement without the need for standard curves, making it an invaluable tool for cancer researchers. The high sensitivity and accuracy of this direct quantification technique allow for the consistent detection of low-abundance mutations and the tracking of changes in biomarker prevalence during repeated testing in longitudinal investigations. dPCR is well-suited for analyzing low-input samples, such as circulating tumor DNA (ctDNA), where detecting small shifts in mutation levels can prove useful in studying tumor burden and response dynamics over time, offering insights that can help refine therapeutic strategies and enhance our understanding of cancer progression.
Our collection of dPCR LNA Mutation Assays was designed to deliver exceptional accuracy and efficiency and can help you unlock the full potential of your oncology research. Here’s what makes our assays stand out:
Select your research area below to view our full offering of ready-to-use dPCR LNA Mutation Assays, each designed to enhance your cancer research with unparalleled precision and efficiency.
*FDA ‘Medical Devices; Laboratory Developed Tests’ final rule, May 6, 2024 and European Union regulation requirements on ‘In-House Assays’ (Regulation (EU) 2017/746 -IVDR- Art. 5(5))
dPCR LNA Mutation Assays are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.
The QIAcuity is intended for molecular biology applications. This product is not intended for the diagnosis, prevention or treatment of a disease. Therefore, the performance characteristics of the product for clinical use (i.e., diagnostic, prognostic, therapeutic or blood banking) is unknown.
The QIAcuityDx dPCR System is intended for in vitro diagnostic use, using automated multiplex quantification dPCR technology, for the purpose of providing diagnostic information concerning pathological states.
QIAcuity and QIAcuityDx dPCR instruments are sold under license from Bio-Rad Laboratories, Inc. and exclude rights for use with pediatric applications. The QIAcuityDx medical device is currently under development and will be available in 20 countries in H2 2024.